Roivant’s Priovant Therapeutics won FDA approval for Lisraya (brepocitinib) to treat adult dermatomyositis, a rare systemic autoimmune disease. The clearance marks Priovant’s first approved product and follows the company’s licensing and development strategy built around JAK1 and TYK2 inhibition. With the approval, Lisraya joins the small set of therapies aimed at inflammatory signaling in dermatomyositis rather than symptom management. Roivant framed the decision as a portfolio milestone for expanding into additional rare immunological indications in development. Clinicians will now have another targeted option for dermatomyositis patients, while the company can accelerate broader evidence generation across other rare inflammatory disorders.